HR Execs on the Move


 
Elicio is committed to transforming the lives of patients and their families by re-engineering the body`s immune response to cancer. By combining expertise in materials science and immunology, Elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. The Elicio Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the “brain center” of the immune response, to significantly amplify and enhance the body`s own system of defenses, to defeat cancer and stop its recurrence. This substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.elicio.com
  • 451 D Street 5th Floor, Suite 501
    Boston, MA USA 02210
  • Phone: 857.209.0050

Executives

Name Title Contact Details
Brian Piekos
Chief Financial Officer Profile
Robert Connelly
Chief Executive Officer Profile

Similar Companies

Elixirgen Therapeutics

A clinical-stage biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines

Cleave Biosciences

Cleave Biosciences is a biopharmaceutical company pioneering the development of novel protein homeostasis inhibitors for the treatment of cancer.

CORRECT PHARMACY

CORRECT PHARMACY is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

NovoBiotic Pharmaceuticals

NovoBiotic Pharmaceuticals is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sangamo

Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients` lives using the company`s industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company is conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington`s disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences.